Recent News

• 08.14.2025 - Leap Therapeutics Reports Second Quarter 2025 Financial Results
• 06.23.2025 - Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
• 06.18.2025 - 2025 Annual Meeting
• 05.13.2025 - Leap Therapeutics Reports First Quarter 2025 Financial Results
• 04.25.2025 - Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
• 04.23.2025 - Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
• 04.15.2025 - Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Recent Filings

• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.23.2025 - 8-K Current report
• 06.23.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 8-K Current report
• 04.28.2025 - ARS Annual Report to Security Holders
• 04.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material